Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary intervention
| Autor: | Nuno Pires, Arnoud van der Laarse, Huibert A. P. Pols, André G. Uitterlinden, Moniek P.M. de Maat, Rune R. Frants, PS Monraats, Aeilko H. Zwinderman, Paul H.A. Quax, Douwe Pons, Johannes Waltenberger, Pieter A. Doevendans, J. Wouter Jukema, Robbert DeWinter, Yue Fang, René A. Tio, Ernst E. van der Wall |
|---|---|
| Přispěvatelé: | Amsterdam Public Health, Epidemiology and Data Science, Amsterdam Cardiovascular Sciences, Cardiology, Cardiologie, RS: CARIM School for Cardiovascular Diseases, Internal Medicine, Hematology, Vascular Ageing Programme (VAP) |
| Rok vydání: | 2010 |
| Předmět: |
Male
EXPRESSION Genotype medicine.medical_treatment Clinical Biochemistry Population stent placement gene polymorphism angioplasty expression prevalence disease era Single-nucleotide polymorphism Bioinformatics Polymorphism Single Nucleotide Calcitriol receptor DISEASE Coronary Restenosis Restenosis Risk Factors Drug Discovery medicine Humans Angioplasty Balloon Coronary ANGIOPLASTY education Genotyping Aged Pharmacology Genetics education.field_of_study business.industry Haplotype Percutaneous coronary intervention Middle Aged medicine.disease Survival Analysis GENE POLYMORPHISM PREVALENCE ERA Haplotypes Conventional PCI Receptors Calcitriol Molecular Medicine Female business Biomarkers Follow-Up Studies STENT PLACEMENT |
| Zdroj: | Expert opinion on therapeutic targets, 14(3), 243-251. Taylor and Francis Ltd. Expert Opinion on Therapeutic Targets, 14(3), 243-251. Informa Healthcare Expert Opinion on Therapeutic Targets, 14(3), 243-251. Taylor & Francis Ltd Expert Opinion on Therapeutic Targets, 14(3), 243-251 EXPERT OPINION ON THERAPEUTIC TARGETS, 14(3), 243-251. TAYLOR & FRANCIS LTD |
| ISSN: | 1744-7631 1472-8222 |
| Popis: | Objective: Restenosis is the main drawback of percutaneous coronary intervention (PCI). Inherited factors may explain part of the risk of restenosis. Recently, the vitamin D receptor (VDR) has been shown to be involved not only in bone metabolism but also in modulating immune responses and cell proliferation. Since the inflammatory response is implicated in restenosis, VDR-gene variants could therefore contribute to the risk of restenosis. Methods/results: Systematic genotyping for 15 haplotype tagging single-nucleotide polymorphisms (SNPs) of the VDR gene was performed with the high throughput TaqMan allelic discrimination assays in the Genetic Determinants of Restenosis (GENDER) population. A haplotype-based survival analysis revealed an association of haplotypes in blocks 2, 3 and 4 of the VDR-gene with the risk of clinical restenosis (p-values 0.01, 0.04 and 0.02 respectively). After adjustment for clinical risk factors for restenosis, the individual effect of the block 2 AA haplotype (p = 0.011) persisted. Conclusions: The present study indicates that VDR plays a role in restenosis after PCI. Therefore, VDR genotype may be used as risk marker for restenosis and may contribute to individual patient screening prior to PCI in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|